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Abstract: Satraplatin is an orally bioavailable platinum chemotherapeutic agent under develop-
ment for several cancer types, including hormone-refractory prostate cancer (HRPC). Satraplatin 
is being developed for the treatment of men with chemorefractory HRPC for several reasons: 1) 
relative ease of administration, 2) potential lack of cross-resistance with other platinum agents, 
3) clinical beneﬁ  ts seen in early studies of HRPC, and 4) an unmet need in this patient population 
after docetaxel failure. As men who have progressed after docetaxel and prednisone have an 
expected median survival of approximately 12 months, there is great opportunity for improved 
palliation in this disease. Satraplatin may provide a palliative beneﬁ  t for these men in terms of 
progression-free survival according to the most recent analyses of the phase III SPARC trial 
comparing satraplatin and prednisone to prednisone alone in the second-line setting for HRPC, 
and is currently under USFDA review for this indication. Whether satraplatin and prednisone 
offer an advantage over docetaxel retreatment or other cytotoxic agents in this setting is an 
unanswered question and worthy of study. Investigation of predictors of platinum sensitivity 
and the use of satraplatin in patients with neuroendocrine subsets of metastatic prostate cancer 
may be warranted given the advances in biomarker and genomic technology and the known 
sensitivity of small cell cancers to platinum agents. Further study of satraplatin alone or in 
combination with docetaxel or other molecular and chemotherapeutic agents seems warranted 
to improve on current outcomes.
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Background
The regimen of docetaxel and prednisone is the preferred systemic treatment in patients 
with progressive metastatic hormone-refractory prostate cancer (HRPC), based on 
improved palliation of disease symptoms, overall survival, and disease response rates 
as compared to mitoxantrone and prednisone, the previous standard of care (Tannock 
et al 2004). Currently, however, there are no approved agents for second-line therapy 
in HRPC patients after docetaxel failure. The goals of therapy in this setting are pal-
liation and quality of life improvement, with strict attention to pain control, treatment 
of fatigue and depression, prevention of spinal cord compression and pathologic frac-
tures, and relief of bladder outlet obstruction. These measures may be accomplished 
through multidisciplinary pain management, anti-depressants and psychosocial support, 
radiotherapy to painful or high risk bony metastatic sites, the use of bisphosphonates, 
and surgical therapy to relieve urethral obstruction (Saad et al 2002).
Current options for these advanced metastatic HRPC patients, who form a relatively 
common subgroup with a 12 month median survival, include clinical trials of novel 
agents, docetaxel retreatment, other cytotoxic agents, additional hormonal manipula-
tions, and best supportive care (Berthold et al 2006). The regimen of mitoxantrone and 
prednisone is currently approved for the palliative care of metastatic HRPC patients Therapeutics and Clinical Risk Management 2007:3(5) 878
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but has minimal activity in the second-line setting (Lin et al 
2006). Estramustine is also US FDA approved for HRPC, 
but is not well studied in the second line setting. Additional 
cytotoxic agents with modest ﬁ  rst or second line palliative 
beneﬁ  t include vinorelbine, paclitaxel, etoposide, cyclo-
phosphamide, capecitabine, cisplatin, and carboplatin, and 
gemcitabine, alone or in combination regimens (Armstrong 
et al 2007; Berthold et al 2006). However, these agents have 
not been studied in adequately controlled or powered trials in 
this setting, and use is limited by toxicity, particularly neuro-
toxicity for vinorelbine and paclitaxel in patients who have 
progressed on docetaxel. Thus, these agents are of unclear 
beneﬁ  t in the second-line setting and second-line therapy 
remains an unﬁ  lled need in the management of HRPC.
Satraplatin [bis-(acetato)-ammine dichloro (cyclohexyl-
amine) platinum IV, also known as JM-216, GPC Biotech 
AG and Pharmion; Munich, Germany and Waltham, 
Massachusetts] is a novel orally formulated platinum analog 
that is currently under study in HRPC among other malig-
nancies (Sternberg 2005). As platinums have typically not 
demonstrated a clinically signiﬁ  cant tumor response rate 
in men with HRPC, satraplatin’s novelty may reside in its 
putative lack of cross-resistance with other platinums com-
pounds (Moore et al 1986; McKeage et al 1997; Fokkema 
et al 1999). While an oral formulation is attractive, efﬁ  cacy 
remains the ideal endpoint over convenience in this palliative 
setting. Its lack of cross-resistance to date remains theoretical 
and based on cell culture studies demonstrating activity in 
cisplatin-resistant models of various tumor types, with the 
potential ability to create DNA adducts that are more resistant 
to DNA nucleotide excision repair enzymes (Sternberg 2005; 
Fokkema et al 2002).
Rationale for use in HRPC
The most compelling argument for an oral non cross-resistant 
platinum analog in HRPC is the potential ability to improve 
the palliative outcomes in this poor-risk group, in terms of 
pain, quality-of-life, and duration of progression-free and 
overall survival. The median survival of patients who have 
progressed despite ﬁ  rst-line docetaxel is approximately 
12 months, and as many of these patients have progressive 
symptoms of disease, palliative therapies are vitally needed 
(Lin et al 2006). Biologically, some prostate cancers are 
known to acquire neuroendocrine features, and indeed 
chromogranin A levels may correlate independently with an 
adverse prognosis in HRPC (Taplin et al 2005). As small cell 
tumors and poorly differentiated neuroendocrine tumors may 
respond to platinum-based therapies, it is rational to explore 
platinum-based therapy in this setting. Indeed, satraplatin had 
clinical activity and was well tolerated in a trial of patients 
with small cell lung cancer (Fokkema et al 1999). However, 
is unclear what the prevalence of neuroendocrine differentia-
tion is in the second-line HRPC setting or if platinum-based 
therapy confers a greater beneﬁ  t than other cytotoxics in this 
subset of patients. Given the paucity of controlled data in the 
second-line setting in HRPC, an oral agent that meets criteria 
for improved palliation would be a welcome addition to the 
chemotherapeutic armamentarium at a clinician’s disposal.
Phase I trials
To date, the dose-limiting toxicity of satraplatin, like other 
platinum analogs, is myelosuppression (McKeage et al 1997; 
Sternberg 2005). Satraplatin has been studied using several 
oral schedules, including a daily for 5 days regimen every 
4–5 weeks at 80–120 mg/m2 and a single dose every 3 weeks 
(McKeage et al 1997). Currently, the daily × 5 regimen has 
emerged as the preferred regimen and for phase III clinical 
trials. Other toxicities (grade 3–4) have included gastroin-
testinal side effects in 7%–10% (predominantly nausea and 
vomiting), hyperglycemia (7.4%), and increases in alkaline 
phosphatase (11%) which may not necessarily be attributable 
to satraplatin (Latif et al 2005; Sternberg 2005; Sternberg et al 
2005; Vouillamoz-Lopez et al 2005). Vomiting (grade 1) 
has been noted in 50%–60% of the cycles in phase I trials 
at the maximal tolerated dose (McKeage et al 1997). To 
date, there have not been major reports of nephrotoxicity, 
ototoxicity, or peripheral neuropathy in over 1500 patients 
studied to date, and therapy has generally been administered 
as an outpatient. However, there have been some concerns 
about the degree of myelosuppression and overall toxicity 
proﬁ  le of satraplatin at the 120 mg/m2 daily × 5 schedule 
based on a phase II study in HRPC patients, which led to 
the selection of a lower dose in the second-line population 
(Latif et al 2005).
Satraplatin pharmacokinetics are linear, with peak con-
centrations occurring at a median of 2 hours, but exhibit a 
high degree of inter-patient variability based on creatinine 
clearance (Vouillamoz-Lopez 2003). Approximately 10% 
of satraplatin is excreted unchanged in the urine, and renal 
excretion seems to be the predominant mode of clearance. 
Satraplatin has not been studied in patients with impaired 
renal clearance, and thus its use in these patients should be 
with caution due to potential increased toxicity. Fortunately, 
the pharmacokinetics of patients who vomited during the 
ﬁ  rst ﬁ  ve days of administration was not statistically different 
than those patients who did not (Vouillamoz-Lopez 2003). Therapeutics and Clinical Risk Management 2007:3(5) 879
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Satraplatin is highly protein bound and little appears as free 
drug in the plasma. Figure 1 shows the structure of satraplatin 
as compared to the other commonly used platinums in the 
clinic, notably cisplatin, carboplatin, and oxaliplatin; a full 
structure-function discussion of these compounds can be 
found elsewhere (Wong and Giandomenico 1999).
Prostate-speciﬁ  c trials
In 2005, Sternberg et al published the results of an aborted 
phase III EORTC study of satraplatin and prednisone com-
pared to prednisone alone in the ﬁ  rst-line setting in HRPC 
(Sternberg et al 2005). Fifty subjects out of an intended 
380 were analyzed before the study was terminated by the 
sponsoring company (Bristol-Myers-Squibb) due to a variety 
of reasons. The dose of satraplatin was 100 mg/m2 day 1–5, 
repeated every 5 weeks along with prednisone 10 mg twice 
daily, with up to 8 cycles administered with prophylactic 
anti-emetics. Despite the small numbers, a greater proportion 
of satraplatin-treated subjects experienced prostrate-speciﬁ  c 
antigen (PSA) declines over 50% (33.3% vs 8.7%), and pro-
gression-free survival favored satraplatin (5.2 vs 2.7 months, 
HR 0.50 and 95% CI 0.28–0.92, see Figure 2). Additionally, 
overall survival favored satraplatin by 3 months (14.9 vs 11.9 
months, p = 0.58) but did not meet statistical signiﬁ  cance 
C. Carboplatin
D. Oxaliplatin
B. Cisplatin
A. Satraplatin
Figure 1 Structures of satraplatin, cisplatin, carboplatin, and oxaliplatin. Satraplatin is a prodrug in which the acetato-based sidechains are released by reduction in the intes-
tines and bioavailability is much higher than older platinum agents. Satraplatin is the only class IV platinum analog shown while the others are class II based on the oxidation 
state of the platinum. Reviewed extensively by Wong and Giandomenico (1999).Therapeutics and Clinical Risk Management 2007:3(5) 880
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(Sternberg et al 2005). Based on these results, satraplatin was 
revived by GPC Biotech and its development continued.
Another trial of satraplatin in patients with HRPC was 
performed as a phase II study (Latif et al 2005). This was 
a multicenter study involving 39 patients in the ﬁ  rst-line 
setting, using 120 mg/m2 on a daily × 5 schedule. Toxicity 
led to the discontinuation of treatment in 13% of patients, 
treatment delay in 77% of the courses, and dose reduction in 
31% of the courses. Despite this toxicity and clear need for 
a lower initial dose, a PSA decline 50% was observed in 
26% (95% CI 10%–50%), and measurable disease response 
in 10% (95% CI 1%–32%). These responses are similar to 
those seen with many other cytotoxics, but suggest a lower 
level of activity in the ﬁ  rst-line setting than docetaxel-based 
chemotherapy (Tannock et al 2004).
A major question for the development of satraplatin is its 
position with other standard agents as treatment for patients 
with HRPC. With the recent approval of docetaxel-based 
therapy by the FDA and European agencies in 2004 for 
treatment of patients with metastatic HRPC, second-line 
therapy is a rational choice with no proven standard-of-care 
(Tannock et al 2004; Lin et al 2006; Berthold et al 2006). 
With this in mind, a phase III, multicenter, randomized, 
placebo-controlled trial of satraplatin and prednisone vs pred-
nisone alone in patients with HRPC treated with one prior 
chemotherapy was initiated in 2003 and accrual completed 
in 2006 (Sternberg 2005). The SPARC trial (Satraplatin and 
Prednisolone Against Refractory Cancer) enrolled patients in 
a 2:1 fashion to satraplatin 80 mg/m2 days 1–5 every 5 weeks 
with prednisone 5 mg twice daily, or to prednisone alone (see 
Figure 3 for schema). This trial accrued 950 patients over 
24 months and had 90% power to detect a 30% improvement 
in progression-free survival (PFS), the primary endpoint. The 
use of a progression endpoint rather than overall survival in 
this setting is controversial, given the unclear surrogacy or 
validation of this measure in this setting, but the decision to 
use this endpoint was made with concordance by the FDA. 
In this study, PFS was deﬁ  ned as a composite of death, tumor 
progression, new skeletal event, or symptomatic disease pro-
gression. Tumor progression was deﬁ  ned by RECIST criteria 
or by two new bone scan lesions rather than through PSA 
criteria, and was evaluated by a blinded independent review 
committee, with assessments every 2 cycles (10 weeks). 
Skeletal events were deﬁ  ned as the clinical need for radio-
therapy or surgery to the bone, new fracture, or initiation of 
bisphosphonate therapy. Symptomatic disease progression 
was deﬁ  ned by the Present Pain Inventory, an increase in 
analgesic consumption, a decline in performance status, or 
by weight loss 10% (Melzack 1975). PSA was not included 
in deﬁ  nitions of progression.
The SPARC trial was closed in September 2006, after 
reaching the primary endpoint of PFS. Results were presented 
in abstract form in February 2007 based on these early data 
(Petrylak et al 2007). In this trial, over 50% of subjects 
had received prior docetaxel therapy and nearly 50% had 
received another form of chemotherapy. Approximately 35% 
Figure 2 Progression-free survival in phase III trial of satraplatin and prednisone vs. prednisone alone in HRPC, terminated early after 50 patients. Reproduced with permis-
sion from Sternberg CN, Whelan P, Hetherington P, et al. 2005. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-
refractory prostate cancer. Oncology, 68:2–9. Copyright © 2005 S. Karger AG.Therapeutics and Clinical Risk Management 2007:3(5) 881
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of subjects had pain scores of 2 or higher on a 5 point scale, 
and baseline characteristics were well balanced, including 
type of progression at entry, use of bisphosphonates, age, and 
performance status. In the satraplatin arm, 19.7% of subjects 
required a dose reduction, 39.4% of subjects required at least 
a one week dose delay, and 15.3% of subjects required dose 
delays in 2 or more cycles. In the satraplatin arm, 40% of 
subjects completed 5 cycles, while only 20% of the predni-
sone treated patients completed 5 cycles, which was attrib-
utable to early progression in the prednisone arm (Petrylak 
et al 2007; Sternberg et al 2007). Toxicity was manageable, 
with 0.6% of subjects on satraplatin therapy developing 
neutropenic fever, 3.8% requiring platelet transfusions, and 
15.9% requiring RBC transfusions. This compares to a rate 
of 0%, 0.3%, and 8% in the prednisone-alone arm. Neu-
ropathy was seen in 0.3% and did not differ from placebo. 
Renal insufﬁ  ciency developed in 0.8% of satraplatin treated 
subjects compared with 0.3% of prednisone-treated sub-
jects. Vomiting was observed in 1.6% of satraplatin treated 
subjects, while no subjects on prednisone alone vomited. 
Other grade 3–4 adverse events that occurred with a higher 
frequency in satraplatin treated subjects included deep vein 
thrombosis (1.6% vs 0%), elevated bilirubin (0.5% vs 0%), 
severe fatigue (4.9% vs 2.6%), and diarrhea (2.1% vs 0%) 
(Petrylak et al 2007).
A hazard ratio of 0.67 (95% CI 0.57–0.77, p < 0.0001) 
for PFS was noted with a median PFS of 11.1 weeks in the 
combination arm, compared to 9.7 weeks in the prednisone 
alone arm, according to independent review (Petrylak et al 
2007). This represents an improvement in median PFS of 
1.3 weeks, or 9 days. Among subjects who had prior 
docetaxel therapy and progressed, the HR for PFS was 
0.67 (95% CI 0.54–0.83, p = 0.0006), with a median sur-
vival favoring satraplatin and prednisone by 1 week (10.1 
vs 9.1 weeks). At 6 months, the proportion with PFS was 
30% vs 17%, favoring satraplatin, and at 12 months, this 
rate was 17% vs 7% (Sternberg et al 2007). While the 
median difference in PFS is clinically modest, the 6- and 
12-month rates of PFS compared with prednisone alone 
may be regarded as significant. These endpoints were 
met due to delays in the time to pain and/or radiologic 
progression, which are clinically significant. However, as 
PFS has not yet been validated as a surrogate for overall 
survival in men with HRPC, the use of a composite PFS 
endpoint should be interpreted with caution (Scher et al 
2007). Finally, prednisone alone is unlikely to be used 
in the second-line setting in the majority of patients, and 
is not regarded as the community standard-of-care, and 
without a comparison to alternative and widely available 
cytotoxic agents such as mitoxantrone, the exact clini-
cal impact of this agent in the oncology community is 
unclear. Overall survival and palliative endpoint results 
are anticipated by late 2007.
Future directions for research
and development
If satraplatin is FDA approved for use in men with HRPC, 
where will it be used in relation to current therapeutic choices 
for patients with HRPC? The SPARC trial represents the 
ﬁ  rst phase III trial in the second-line setting in HRPC, and 
should be examined closely for its impact on palliation and 
quality-of-life (QoL) as well as PFS. If palliative endpoints 
are met with overall survival endpoints, then this likely 
represents a treatment advance however modest the absolute 
differences are, and the issues will be those of risk-beneﬁ  t 
proﬁ  les, cost effectiveness, and therapeutic niche including 
future combinatorial directions. The lack of a true control 
group with mitoxantone and prednisone, a proven palliative 
Figure 3 Trial schema for the randomized phase III SPARC trial which was recently completed in second-line HRPC.  Anti-emetics are standard in the satraplatin arm, while 
an anti-emetic placebo is used in the standard prednisone alone placebo controlled arm (two placebos used).Therapeutics and Clinical Risk Management 2007:3(5) 882
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combination in HRPC, limits the interpretability of the 
activity of satraplatin as a palliative agent. In our opinion, 
PFS may be considered a reasonable measure of clinical 
beneﬁ  t if the results are substantially improved over the 
existing standard-of-care. However, if overall survival is not 
met despite a statistical improvement in PFS, there may be 
reason to question the value of intermediate outcomes such 
as PFS as a surrogate primary endpoint for overall survival in 
phase III trials in men with HRPC. Given the potential for a 
clinically relevant palliative beneﬁ  t for men in the second-line 
setting and the lack of available proven therapies, satraplatin 
may represent a signiﬁ  cant treatment advance.
Moving forward, what role will satraplatin play in the 
clinic? Clearly, the SPARC trial leaves open many ques-
tions, including 1) the degree of pain palliation, 2) the 
utility of satraplatin combination regimens in the ﬁ  rst- and 
second-line setting, 3) the use of biomarkers to predict the 
subgroup that demonstrate satraplatin sensitivity (ie, serum 
chromogranin A, genomic markers), and 4) the beneﬁ  ts 
of satraplatin compared with already approved and less 
expensive cytotoxic agents, such as mitoxantrone and pred-
nisone, docetaxel retreatment, low-dose cyclophosphamide, 
and other regimens. Mature data on speciﬁ  c palliative and 
overall survival endpoints for this trial are anticipated in late 
2007 and will shed light on the prospects for this agent in 
the future. Satraplatin is currently under FDA review based 
on the SPARC trial data. If the FDA review of the palliative 
and primary endpoints of the SPARC trial is favorable, the 
likely indication for satraplatin would be for the palliative 
management of men with HRPC who have progressed despite 
ﬁ  rst-line chemotherapy.
Conclusion
The development of satraplatin as an anti-cancer agent has 
progressed to phase III trials in HRPC, which have demon-
strated improvements in PFS, which may indicate a clinically 
relevant beneﬁ  t. Further data on speciﬁ  c elements of clinical 
beneﬁ  t, including pain control, quality of life, and overall 
survival, are awaited in 2007 as this agent is reviewed for 
FDA approval. The beneﬁ  ts seen in progression may be of 
clinical signiﬁ  cance, given the lack of approved therapies in 
the second-line setting; however, progression as an endpoint 
is not yet a proven surrogate for overall survival or clinical 
beneﬁ  t in HRPC. This trial does demonstrate the need for hard 
clinical outcomes in HRPC, and for rigorously deﬁ  ned deﬁ  ni-
tions of progression that meet surrogacy criteria for overall 
survival (Armstrong et al 2007). The utility of satraplatin will 
likely reside in combination therapy in the ﬁ  rst- or second-line 
setting, using docetaxel, other taxane-based strategies, or novel 
biologic agents, and as single-agent palliation in those patients 
who have progressed after docetaxel and who prefer an oral 
regimen (Jones et al 2002). It is also essential to further deﬁ  ne 
subgroups of HRPC that are likely to exhibit platinum sensi-
tivity, as exempliﬁ  ed by the histologic or genomic approaches 
taken in lung cancer (Olaussen et al 2006; Potti et al 2006).
References
Armstrong AJ, Carducci MA. 2005. Chemotherapy for advanced prostate 
cancer. In Principles and Practice of Prostate Cancer. 1st ed. Kirby RS, 
Partin A, Feneley M, et al. eds. London: Martin Dunitz.
Armstrong AJ, Garrett-Mayer ES, de Wit R, et al. 2007. Limitations of 
the current progression-free survival (PFS) deﬁ  nition in hormone-
refractory prostate cancer (HRPC): Beneﬁ  t associated with continuation 
of docetaxel beyond TAX327 protocol-deﬁ  ned progression [abstract]. 
Proceedings of the American Society of Clinical Oncology Prostate 
Cancer Symposium. In press.
Berthold DR, Sternberg CN, Tannock IF. 2005. Management of advanced 
prostate cancer after ﬁ  rst-line chemotherapy. J Clin Oncol, 23:8247–52.
Fokkema E, Groen HJM, Bauer J, et al. 1999. Phase II study of oral plati-
num drug JM216 as ﬁ  rst-line treatment in patients with small-cell lung 
cancer. J Clin Oncol, 17:3822–7.
Fokkema E, Groen HJM, Helder MN, et al. 2002. JM216-, JM118-, and 
cisplatin induced cytotoxicity in relation to platinum-DNA adduct 
formation, glutathione levels and p53 status in human cell lines with 
different sensitivities to cisplatin. Biochem Pharmacol, 63:1989–96.
Jones S, Hainsworth J, Burris HA, et al. 2002. Phase I study of JM-216 (an 
oral platinum analog) in combination with paclitaxel in patients with 
advanced malignancies. Invest New Drugs, 20:55–61
Latif T, Wood L, Connell C, et al. 2005. Phase II study of oral bis(aceto) 
ammine dicloro (cyclohexamine) platinum (IV) (JM216, BMS 182–751) 
given daily × 5 in hormone refractory prostate cancer (HRPC). Invest 
New Drugs, 23:79–84.
Lin AM, Rosenberg JE, Weinberg VK, et al. 2006. Clinical outcome of 
taxane-resistant hormone-refractory prostate cancer patients treated with 
subsequent chemotherapy (ixabepilone or mitoxantrone/prednisone) 
[abstract]. J Clin Oncol, 24:4558.
McKeage MJ, Raynaud F, Ward J, et al. 1997. Phase I and pharmacokinetic 
study of an oral platinum complex given daily for 5 days in patients 
with cancer. J Clin Oncol, 15:2691–700.
Melzack R. 1975. The McGill Pain Questionnaire:major properties and 
scoring methods. Pain, 1:277–99.
Moore MR, Troner MB, DeSimone P, et al. 1986. Phase II evaluation of 
weekly cisplatin in metastatic hormone-resistant prostate cancer:a 
southeastern cancer study group trial. Cancer Treat Rep, 70:541–2.
Olaussen KA, Dunant A, Fouret P, et al. 2006. DNA Repair by ERCC1 in 
non–small–cell lung cancer and cisplatin-based adjuvant chemotherapy. 
N Engl J Med, 355:983–91.
Petrylak D, Sartor O, Witje F, et al. 2007. A Phase III, randomized, double-
blind trial of satraplatin and prednisone vs. placebo and prednisone for 
patients with hormone refractory prostate cancer (HRPC) [abstract]. 
Proc Am Soc Clin Oncol Prostate Cancer Symposium. Abstract 145.
Potti A, Mukherjee S, Petersen R, et al. 2006. A genomic strategy to reﬁ  ne 
prognosis in early-stage non–small-cell lung cancer. N Engl J Med, 
355:570–80.
Saad F, Gleason D, Murray R, et al. 2002. Long term efﬁ  cacy of zole-
dronic acid for the prevention of skeletal complications in patients 
with hormone-refractory metastatic prostate cancer. J Natl Cancer 
Inst, 96:879–82.
Scher HI, Warren M, Heller G. 2007. The association between measures 
of progression and survival in castrate-metastatic prostate cancer. Clin 
Cancer Res, 13:1488–92.Therapeutics and Clinical Risk Management 2007:3(5) 883
Satraplatin in HRPC
Sternberg CN. 2005. Satraplatin in the treatment of hormone-refractory 
prostate cancer. BJU Int, 96:990–4.
Sternberg CN, Whelan P, Hetherington P, et al. 2005. Phase III trial of satra-
platin, an oral platinum plus prednisone vs. prednisone alone in patients 
with hormone-refractory prostate cancer. Oncology, 68:2–9.
Sternberg CN, Petrylak D, Witjes F, et al. 2007. Satraplatin (S) demonstrates 
signiﬁ  cant clinical beneﬁ  ts for the treatment of patients with HRPC:Results 
of a randomized phase III trial. Proc Am Soc Clin Oncol, 25:5019.
Tannock IF, de Wit R, Berry WR, et al. 2004. Docetaxel plus prednisone 
or mitoxantrone plus prednisone for advanced prostate cancer. N Engl 
J Med, 351:1502–12.
Taplin M, George DJ, Halabi S, et al. 2005. Prognostic signiﬁ  cance of 
plasma chromogranin A levels in patients with hormone-refractory 
prostate cancer treated in cancer and leukemia group B study 9480. 
Urology, 66:386–91.
Vouillamoz-Lopez S, Buclin T, Lejeune F, et al. 2003. Pharmacokinetics 
of satraplatin (JM216), an oral platinum (IV) complex under daily oral 
administration for 5 or 14 days. Anticancer Res, 23:2757–66.
Wong E, Giandomenico CM. 1999. Current status of platinum based anti-
tumor drugs. Chem Rev, 99:2451–466.